Regulatory News: NANOBIOTIX(Paris:NANO) (Euronext: NANO ISIN: FR0011341205 the "Company"), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today an...
Original Article: Nanobiotix announces first quarter 2019 revenue